TOPLINE:

An oral therapy targeting toll-like receptors (TLR) 7 and 8 reduced disease activity in patients with cutaneous lupus erythematosus (CLE) or systemic lupus erythematosus (SLE) with active lupus rash.

METHODOLOGY:

Cohort A of the phase 2 WILLOW study included patients with CLE and patients with mild SLE and active skin manifestation for whom no approved treatments currently exist.

In the study of the oral, small molecule TLR 7/8 inhibitor enpatoran, researchers randomly assigned 100 patients, all receiving standard-of-care medications, to placebo, 25 mg enpatoran, 50 mg enpatoran, or 100 mg enpatoran twice daily for 24 weeks.

The primary endpoint was percent change in CL Disease Area and Severity Index Activity (CLASI-A) from baseline to week 16.

TAKEAWAY:

Patients taking en

See Full Page